Prognostic Implication of the m6A RNA Methylation Regulators in Rectal Cancer

Yajie Chen,Shanshan Wang,William C. Cho,Xiang Zhou,Zhen Zhang
DOI: https://doi.org/10.3389/fgene.2021.604229
IF: 3.7
2021-06-03
Frontiers in Genetics
Abstract:N6-methyladenosine (m 6 A) is a very common and abundant RNA modifications occurring in nearly all types of RNAs. Although the dysregulated expression of m 6 A regulators is implicated in cancer progression, our understanding of the prognostic value of the m 6 A regulators in rectal cancer is still quite limited. In this study, we analyzed the RNA expression levels of the 17 m 6 A regulator genes of 95 rectal cancer and 10 normal rectal samples from the The Cancer Genome Atlas Rectum Adenocarcinoma (TCGA-READ) dataset. Lasso regression analysis was conducted to build a prognostic model and calculate the risk score. The rectal cancer patients were then devided into the high-risk and low-risk groups according to the mean risk score. The prognostic value of the identified model was separately evaluated in the TCGA-READ and GSE87211 datasets. GSEA was conducted to analyze the functional difference of high-risk and low-risk rectal cancer patients. Our analysis revealed that rectal cancer patients with lower expression of YTHDC2 and METTL14 had a remarkable worse overall survival ( P < 0.05). The prognostic value of the model was validated in GSE87211 datasets, with AUC = 0.612 for OS and AUC = 0.651 for RFS. Furthermore, the m 6 A modification-based risk score system is associated with activation of distinct signaling pathways, such as DNA repair, epithelial-mesenchymal transition, G 2 M checkpoint and the MYC pathway, that may contribute to the progression of rectal cancer. In conclusion, our findings demonstrated that the m 6 A RNA methylation regulators, specifically YTHDC2 and METTL14, were significantly down-regulated and might be potential prognostic biomarkers in rectal cancer.
genetics & heredity
What problem does this paper attempt to address?